Short answer
Day One Biopharmaceuticals, Inc. (DAWN) filed an 8-K current report with the SEC on April 23, 2026 reporting Item 1.02 (Termination of a Material Definitive Agreement), Item 2.01 (Completion of Acquisition or Disposition of Assets), Item 3.01 (Notice of Delisting), Item 5.02 (Departure/Election of Directors or Officers), Item 5.03 (Amendments to Articles of Incorporation or Bylaws). Employee Stock Purchase Plan terminated immediately before merger effective time.
- This filing includes Item 3.01, an item that often signal trouble.
Day One Biopharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.02 · Termination of a Material Definitive Agreement
- Employee Stock Purchase Plan terminated immediately before merger effective time
- All Day One stock plans terminated at merger effective time
- Equity Distribution Agreement with Piper Sandler and JonesTrading terminated effective April 20, 2026
- Termination ends the company’s equity issuance program under the June 1, 2022 Sales Agreement
Item 2.01 · Completion of Acquisition or Disposition of Assets
- Servier/Parent acquired 100% of Day One’s voting securities, resulting in a complete change of control
- Approximately $2.5 billion equity value paid in cash and cash-like instruments
- Transaction consideration funded by Servier and Parent using existing liquidity
- No known arrangements expected to trigger another control changeագայում
Item 3.01 · Notice of Delisting
- Nasdaq trading halt began 8:00 p.m. ET on April 22, 2026
- Merger consummated before market open on April 23, 2026
- Form 25 initiated delisting and deregistration of Day One shares under Exchange Act Section 12(b)
- Planned Form 15 would terminate Section 12(g) registration and suspend SEC reporting obligations
- Public-market liquidity and ongoing shareholder disclosures expected to end following merger completion
Item 5.02 · Departure/Election of Directors or Officers
- Merger completed with Purchaser’s directors, David K. Lee and Danielle Button, becoming Surviving Corporation directors
- Eight incumbent directors departed, including Jeremy Bender, Habib Dable, and Scott Garland
- Departures unrelated to disagreements over operations, policies, or practices
- David K. Lee became President and Secretary; Danielle Button became Treasurer
- All incumbent Company officers removed immediately after the merger effective time
Item 5.03 · Amendments to Articles of Incorporation or Bylaws
- Merger-effective charter amendment replaced Day One’s prior certificate of incorporation in full
- Purchaser’s pre-merger bylaws became Day One’s governing bylaws
- Revised charter and bylaws may alter shareholder rights and governance following the merger
- Investors should review Exhibits 3.1 and 3.2 for voting, board, and corporate-governance changes
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Day One Biopharmaceuticals, Inc. 8-K filings
Get the next DAWN 8-K as it lands
Follow DAWN for push alerts, or ask the research agent what this filing means.